At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 258 enrolled
Drug / intervention
Etanercept +1 morebiological
Likely dose
Etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Canadian Methotrexate and Etanercept Outcome Study: An Open Label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis (CAMEO)
In Brief
A Phase 4 clinical trial evaluating Etanercept and Methotrexate for Rheumatoid Arthritis. Completed, enrolled 258 participants across 28 sites.
Detailed Summary
The purpose of the study is to evaluate the use of etanercept in the treatment of rheumatoid arthritis with or without methotrexate treatment over a 24 month period
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesCanada
CollaboratorsWyeth is now a wholly owned subsidiary of Pfizer
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartJun 2008
Primary CompletionDec 2012
Study CompletionFeb 2013
TodayJul 2026
First PostedApr 8, 2008
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2012
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 18.2 years ago
Interventions
Etanerceptbiological
Commercially available etanercept administered subcutaneously at 50 mg/week.
Methotrexatedrug
Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)